Effectiveness of Polysaccharide Pneumococcal Vaccine in HIV-Infected Patients: a Case-Control Study | Zendy

María Luz Pintos Peñaranda | Zendy; Vicenç Falcó | Zendy; Antoni Payeras | Zendy; Queralt Jordano | Zendy; Adrián Curran | Zendy; A Pareja | Zendy; Gloria Sampériz | Zendy; David Dalmau | Zendy; Esteban Ribera | Zendy; Melchor Riera | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effectiveness of Polysaccharide Pneumococcal Vaccine in HIV-Infected Patients: a Case-Control Study

Author(s) -

María Luz Pintos Peñaranda,

Vicenç Falcó,

Antoni Payeras,

Queralt Jordano,

Adrián Curran,

A Pareja,

Gloria Sampériz,

David Dalmau,

Esteban Ribera,

Melchor Riera

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/520977

Subject(s) - medicine , odds ratio , streptococcus pneumoniae , confidence interval , pneumonia , pneumococcal polysaccharide vaccine , pneumococcal pneumonia , pneumococcal infections , incidence (geometry) , pneumococcal vaccine , immunology , gastroenterology , antibiotics , pneumococcal disease , microbiology and biotechnology , biology , physics , optics

Polysaccharide pneumococcal vaccine (PPV) is recommended among human immunodeficiency virus (HIV)-infected patients, although its effect in reducing the incidence of pneumonia or invasive pneumococcal disease is not well established. Our objective was to determine the effectiveness of 23-valent PPV in HIV-infected adults and the risk factors for pneumococcal pneumonia or invasive pneumococcal disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research